<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920305-0099</DOCNO><DOCID>920305-0099.</DOCID><HL>   Technology:   Repligen's Experimental Drug</HL><DATE>03/05/92</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   RGEN</CO><MS>TECHNOLOGY (TEC)</MS><IN>ADVANCED TECHNOLOGY MEDICAL DEVICES (MDV)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>SCIENCE andamp; TECHNOLOGY (SCN)</NS><RE>MASSACHUSETTS (MA)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   CAMBRIDGE, Mass. -- Repligen Corp. said it plans laterthis year to begin clinical trials with a geneticallyengineered drug for reversing effects of the anticoagulantdrug heparin.   The company added that in a recent animal study itconducted with Temple University, the drug, plateletfactor-4, showed fewer toxic effects than a drug now used toreverse heparin's effects. The study also indicated theexperimental drug is as effective as the existing alternativedrug, Repligen said.</LP><TEXT>   Heparin often is administered to patients before heartsurgery to prevent dangerous blood clots from forming.   Repligen recently formed a $45 million research anddevelopment partnership to develop platelet factor-4 as atreatment for certain cancers and other disorders.</TEXT></DOC>